Summary
Boston Scientific Corporation (BSX) reported strong net sales growth of 6.7% to $12.68 billion for the fiscal year ended December 31, 2022. This growth was driven by a combination of operational expansion, strategic acquisitions, and a diverse product portfolio, particularly in the Cardiovascular and MedSurg segments. Despite facing headwinds from foreign currency fluctuations and global supply chain challenges, the company demonstrated resilience. Financially, BSX reported a net income of $642 million, or $0.45 per diluted share. On an adjusted basis, excluding certain charges and credits, net income was $2.46 billion, or $1.71 per diluted share. The company maintained a robust balance sheet with $928 million in unrestricted cash and cash equivalents and a strong credit facility. The company's strategic imperatives focus on strengthening category leadership, expanding into high-growth adjacencies, and driving global expansion, which are supported by ongoing investments in research and development.
Financial Highlights
53 data points| Revenue | $12.68B |
| Cost of Revenue | $3.96B |
| Gross Profit | $8.73B |
| SG&A Expenses | $4.52B |
| Operating Expenses | $7.08B |
| Operating Income | $1.65B |
| Interest Expense | $470.00M |
| Net Income | $698.00M |
| EPS (Basic) | $0.45 |
| EPS (Diluted) | $0.45 |
| Shares Outstanding (Basic) | 1.43B |
| Shares Outstanding (Diluted) | 1.44B |
Key Highlights
- 1Net sales increased by 6.7% to $12.68 billion in 2022, driven by operational growth and acquisitions.
- 2Reported net income was $642 million ($0.45 per diluted share), with adjusted net income of $2.46 billion ($1.71 per diluted share).
- 3The Cardiovascular segment remains the largest contributor to net sales, with Cardiology products generating $5.93 billion.
- 4The MedSurg segment also showed growth, with Urology sales up 12.0% and Endoscopy sales up 3.7%.
- 5The company continues to invest in R&D, with R&D expenses increasing by 10% to $1.32 billion.
- 6Boston Scientific repurchased no shares in 2022 but has $1 billion remaining on its stock repurchase program authorization.
- 7The company announced a new global restructuring program (2023 Restructuring Plan) expected to result in pre-tax charges of $450-$550 million to improve operating performance.